Clinical Trials | September 23, 2025
Roche's Giredestrant combination meets phase III endpoints in advanced breast cancer
Importantly, the combination of giredestrant and everolimus was well tolerated
Importantly, the combination of giredestrant and everolimus was well tolerated
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
The state-of-the-art facility is a 450-bedded, multi-specialty tertiary care hospital,
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
Subscribe To Our Newsletter & Stay Updated
